1. Home
  2. NERV vs RBNE Comparison

NERV vs RBNE Comparison

Compare NERV & RBNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NERV
  • RBNE
  • Stock Information
  • Founded
  • NERV 2007
  • RBNE 2024
  • Country
  • NERV United States
  • RBNE Cyprus
  • Employees
  • NERV N/A
  • RBNE N/A
  • Industry
  • NERV Biotechnology: Pharmaceutical Preparations
  • RBNE Marine Transportation
  • Sector
  • NERV Health Care
  • RBNE Consumer Discretionary
  • Exchange
  • NERV Nasdaq
  • RBNE Nasdaq
  • Market Cap
  • NERV 14.6M
  • RBNE 15.8M
  • IPO Year
  • NERV 2014
  • RBNE N/A
  • Fundamental
  • Price
  • NERV $4.78
  • RBNE $1.14
  • Analyst Decision
  • NERV Hold
  • RBNE
  • Analyst Count
  • NERV 1
  • RBNE 0
  • Target Price
  • NERV $5.00
  • RBNE N/A
  • AVG Volume (30 Days)
  • NERV 9.3M
  • RBNE 3.6M
  • Earning Date
  • NERV 11-05-2025
  • RBNE 10-23-2025
  • Dividend Yield
  • NERV N/A
  • RBNE N/A
  • EPS Growth
  • NERV N/A
  • RBNE N/A
  • EPS
  • NERV 1.48
  • RBNE N/A
  • Revenue
  • NERV N/A
  • RBNE N/A
  • Revenue This Year
  • NERV N/A
  • RBNE N/A
  • Revenue Next Year
  • NERV N/A
  • RBNE N/A
  • P/E Ratio
  • NERV $3.06
  • RBNE N/A
  • Revenue Growth
  • NERV N/A
  • RBNE N/A
  • 52 Week Low
  • NERV $1.15
  • RBNE $1.13
  • 52 Week High
  • NERV $12.46
  • RBNE $20.57
  • Technical
  • Relative Strength Index (RSI)
  • NERV 63.84
  • RBNE N/A
  • Support Level
  • NERV $4.27
  • RBNE N/A
  • Resistance Level
  • NERV $12.46
  • RBNE N/A
  • Average True Range (ATR)
  • NERV 0.86
  • RBNE 0.00
  • MACD
  • NERV 0.16
  • RBNE 0.00
  • Stochastic Oscillator
  • NERV 24.84
  • RBNE 0.00

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

About RBNE Robin Energy Ltd. Common Stock

Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.

Share on Social Networks: